Jane Street’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,231
| Closed | -$381K | – | 13112 |
|
|
2026
Q1 | $381K | Sell |
7,231
-81,606
| -92% | -$3.35M | ﹤0.01% | 8664 |
|
|
2025
Q4 | $3.59M | Buy |
88,837
+24,589
| +38% | +$568K | ﹤0.01% | 3747 |
|
|
2025
Q3 | $483K | Buy |
+64,248
| New | +$410K | ﹤0.01% | 7951 |
|
|
2025
Q1 | – | Sell |
-36,679
| Closed | -$150K | – | 10593 |
|
|
2024
Q4 | $203K | Sell |
36,679
-84,914
| -70% | -$575K | ﹤0.01% | 8384 |
|
|
2024
Q3 | $1.01M | Sell |
121,593
-21,739
| -15% | -$179K | ﹤0.01% | 5858 |
|
|
2024
Q2 | $976K | Buy |
143,332
+95,680
| +201% | +$580K | ﹤0.01% | 5822 |
|
|
2024
Q1 | $313K | Sell |
47,652
-16,801
| -26% | -$110K | ﹤0.01% | 7497 |
|
|
2023
Q4 | $418K | Buy |
+64,453
| New | +$341K | ﹤0.01% | 7070 |
|
|
2023
Q3 | – | Sell |
-24,178
| Closed | -$153K | – | 9375 |
|
|
2023
Q2 | $212K | Sell |
24,178
-125,183
| -84% | -$1.46M | ﹤0.01% | 7618 |
|
|
2023
Q1 | $1.77M | Buy |
149,361
+127,854
| +594% | +$1.22M | ﹤0.01% | 4029 |
|
|
2022
Q4 | $219K | Buy |
21,507
+8,252
| +62% | +$54.9K | ﹤0.01% | 7530 |
|
|
2022
Q3 | $78K | Buy |
+13,255
| New | +$49.3K | ﹤0.01% | 8762 |
|
|
2021
Q3 | – | Sell |
-11,973
| Closed | -$147K | – | 10715 |
|
|
2021
Q2 | $147K | Buy |
+11,973
| New | +$204K | ﹤0.01% | 9057 |
|
Other funds holding TERN
Jane Street's TERN Position: Q2 2026 in Review
Jane Street sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 7,231 shares — an estimated $381K sold.
Jane Street first reported a position in TERN in Q2 2021 and held it in 13 quarters. The position peaked at $3.59M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Jane Street reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jane Street sold 7,231 Terns Pharmaceuticals shares in Q2 2026, an estimated $381K.
- Jane Street first reported a position in Terns Pharmaceuticals in Q2 2021 and held it in 13 quarters.
- Jane Street's Terns Pharmaceuticals position peaked at $3.59M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.